Atossa Therapeutics
ATOS
45 hedge funds and large institutions have $11.9M invested in Atossa Therapeutics in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 17 reducing their positions, and 8 closing their positions.
1,117% more call options, than puts
Call options by funds: $779K | Put options by funds: $64K
25% more capital invested
Capital invested by funds: $9.49M → $11.9M (+$2.38M)
0.08% less ownership
Funds ownership: 0.94% → 0.86% (-0.08%)
12% less funds holding
Funds holding: 51 → 45 (-6)
59% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 17
75% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$67.9K |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$9.52K |
| 3 |
EMG
ETF Managers Group
Summit,
New Jersey
|
+$8.07K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$6.8K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.12K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$484K |
| 2 |
BlackRock
New York
|
-$191K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$105K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$103K |
| 5 |
Millennium Management
New York
|
-$74.1K |
ATOS Hedge Fund Activity: Q1 2023 in Review
45 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q1 2023, worth a combined $11.9M — up 25% from $9.49M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ATOS and 2 opened new positions — a net loss of 6 holders — while 17 trimmed existing stakes and 7 added.
The largest buyer was Renaissance Technologies, adding an estimated $67.9K. The largest seller was D.E. Shaw & Co, cutting an estimated $484K.
- 45 institutional investors held Atossa Therapeutics (ATOS) as of Q1 2023, down from 51 in Q4 2022.
- Funds reported $11.9M of Atossa Therapeutics stock for Q1 2023, up 25% quarter-over-quarter.
- 2 funds opened new Atossa Therapeutics positions in Q1 2023 and 8 closed out, a net change of -6 holders.
- The largest Atossa Therapeutics buyer in Q1 2023 was Renaissance Technologies, an estimated $67.9K added.
- The largest Atossa Therapeutics seller in Q1 2023 was D.E. Shaw & Co, an estimated $484K sold.
Based on aggregated 13F filings for Q1 2023.